Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer

Objective: This study aims to determine the diagnosis and prediction value of serum miR-184 and miR-191 levels in patients with non-small-cell lung cancer (NSCLC). Methods: One hundred patients with NSCLC were enrolled (NSCLC group) and treated with gefitinib. In addition, 59 pneumonia cases (pneumonia group) and 51 healthy cases in the corresponding period (normal group) were included. Serum miR-184 and miR-191 expressions were detected by real-time quantitative polymerase chain reaction. Furthermore, the relationships between serum miR-184 and miR-191 expressions and clinicopathological parameters were analyzed. The use of serum miR-184 and miR-191 levels in the diagnosis of NSCLC and the prediction of treatment effectiveness and 3-year overall survival (OS) were assessed by the receiver operating characteristic curve. Hazard factors affecting the efficacy of treatment in patients with NSCLC were determined by logistic regression. Results: The serum levels of miR-184 in the NSCLC group were significantly lower than those in the pneumonia group and normal group, whereas miR-191 expression was significantly higher in the NSCLC group. Serum miR-184 and miR-191 levels were closely correlated with smoking history, the tumor node metastasis (TNM) stage, and the degree of pathological differentiation. The area under curve (AUC) of serum miR-184 combined with miR-191 in the diagnosis of patients in the NSCLC group and normal group, NSCLC group and pneumonia group, and the efficacy of treatment in patients with NSCLC was 0.925, 0.929, and 0.916, respectively. The AUC of serum miR-184 and miR-191 for the 3-year OS in patients with NSCLC was 0.869 and 0.879, respectively. Smoking history, the degree of pathological differentiation, local treatment, miR-184, and miR-191 were independent risk factors that affected treatment efficacy. Conclusion: Serum miR-184 and miR-191 levels can potentially be used as molecular markers to diagnose and predict the curative effect of treatment in patients with NSCLC.

Download Full-text

Successful treatment of pulmonary lymphangitic carcinomatosis by anlotinib in 14 Chinese patients with advanced non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e21064 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e21064-e21064

Author(s):

Shencun Fang ◽

Wanwan Cheng ◽

Yingming Zhang ◽

Haitao Zhang ◽

Si Li ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Lymphatic Metastasis ◽

Small Cell ◽

Smoking History ◽

Wild Type ◽

Small Cell Lung ◽

The Impact ◽

Lymphangitic Carcinomatosis

e21064 Background: Pulmonary lymphangitic carcinomatosis (PLC) occurs in 6%-8% of intrathoracic metastases among malignant tumor. The median survival was only 2.0 months from time of pulmonary symptoms to death in cases during 2000-2018, which is a poor prognosis. Effective interventions were needed besides standard chemotherapy and symptomatic support. Anlotinib showed a critical effect on lymphangiogenesis, and lymphatic metastasis in mouse models of lung adenocarcinoma, it might be a therapeutic option for tumor lymphatic metastasis. In this study, we retrospectively analyzed the efficacy and safety of anlotinib for PLC in patients with Non-small Cell Lung Cancer (NSCLC). Methods: We retrospectively investigated NSCLC patients with PLC at our hospital between May 2018 and November 2020, who received anlotinib monotherapy or combined therapy for PLC. Data were analyzed for progression-free survival (PFS), overall survival (OS), objective response rate(ORR), disease control rate(DCR) and adverse events (AE). The impact of clinical and genomic factors on PFS and OS were also assessed. Results: A total of 14 patients were enrolled with a median age of 64 years. 10(71.4%) were male, 4(28.6%) has smoking history, 10(71.4%) of patients had a performance status of 2-3. 9, 3, 2 patients had TP53 mutation, EGFR mutation, ALK fusion respectively. 9(64.3%) patients received anlotinib monotherapy. Of 14 patients, 8 achieved partial response (PR), 5 presented stable disease (SD), 1 had progressed disease. The ORR and DCR were 57.1% and 92.9% respectively. The median PFS was 3.1 months (95% CI: 2.0-4.2), the median OS for 1, 2, ≥3 line were 13 months, 7.2 months, 5.2 months, respectively. Median PFS and OS (≥3 line) were significantly longer for patients with TP53-mutant tumors compared with those with TP53–wild-type tumors (median PFS: 7 vs. 1.1 months, median OS (≥3 line): 6.8 vs. 1.9 months). No difference of PFS and OS (≥3 line) was found between EGFR or ALK alteration and the corresponding wild type patients. The most frequently reported AEs were high blood pressure (11, 78.6%), hand foot syndrome (6, 42.9%), diarrhea (5, 35.7%), fatigue (4, 28.6%), hoarseness (3, 21.4%), proteinuria (2, 14.3%) and stomatitis (2, 14.3%). Conclusions: Anlotinib presented favorable efficacy in patients with pulmonary lymphangitic carcinomatosis and conferred considerable survival benefit compared with previous studies, especially in patients harboring TP53 mutations. The AEs were manageable. These indicated that anlotinib can be a promising therapeutic treatment of PLC. More clinical data is needed to validate this finding.

Download Full-text

RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djab159 ◽

2021 ◽

Cited By ~ 1

Author(s):

Ashley M Hopkins ◽

Ganessan Kichenadasse ◽

Jessica M Logan ◽

Andrew Rowland ◽

Michael J Sorich

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitor ◽

Checkpoint Inhibitor ◽

Small Cell ◽

Smoking History ◽

Small Cell Lung ◽

Potential Predictor

Download Full-text

B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer

Journal of Clinical Pathology ◽

10.1136/jclinpath-2017-204860 ◽

2018 ◽

Vol 71 (7) ◽

pp. 642-647 ◽

Cited By ~ 4

Author(s):

Liuwei Gao ◽

Hua Zhang ◽

Bin Zhang ◽

Jinfang Zhu ◽

Chen Chen ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Disease Free Survival ◽

Small Cell ◽

Clinicopathological Parameters ◽

Small Cell Lung ◽

Nsclc Tissue ◽

Clinical Prognosis ◽

Nsclc Patients

ObjectiveThe aim of this study was to evaluate the expression of beta-1,3-N-acetylglucosaminyltransferase-3 (B3GNT3) in non-small cell lung cancer (NSCLC) patients and to investigate the relevance of B3GNT3 expression in tumour prognosis.MethodsIn this study, B3GNT3 expression was examined in five pairs of resectable NSCLC tissue by Western blot and in 42 pairs of resectable NSCLC tissue by quantitative real-time PCR (qRT-PCR). Immunohistochemistry and statistical analysis were performed to assess the relationship between B3GNT3 expression scores and clinicopathological parameters, as well as clinical prognosis in a retrospective cohort of 176 NSCLC patients.ResultsBoth B3GNT3 mRNA and protein expression levels were significantly higher in NSCLC tissue than in adjacent normal tissue. In the 176 NSCLC cases, a high B3GNT3 expression level was positively correlated with lymph node metastasis (P<0.001) and advanced TNM stage (P=0.043). Kaplan-Meier analysis indicated that patients with high B3GNT3 expression had significantly lower disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001) than those with low B3GNT3 expression. Moreover, in the multivariate analyses, B3GNT3 expression was an independent prognostic factor for DFS (HR 0.329, 95% CI 0.213 to 0.508, P<0.001) and OS (HR 0.383, 95% CI 0.249 to 0.588, P<0.001).ConclusionsOur study demonstrated that high expression of B3GNT3 was associated with unfavourable DFS and OS in NSCLC patients, suggesting that B3GNT3 might be a potential prognostic biomarker for NSCLC.

Download Full-text

Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation

BMC Pulmonary Medicine ◽

10.1186/s12890-019-0951-2 ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

Sung Woo Moon ◽

Moo Suk Park ◽

Young Sam Kim ◽

Joon Jang ◽

Jae Ho Lee ◽

...

Keyword(s):

Lung Cancer ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Group Performance ◽

Small Cell ◽

Smoking History ◽

Small Cell Lung ◽

Nsclc Patients

Abstract Background In non-small cell lung cancer (NSCLC) patients, concomitant idiopathic pulmonary fibrosis (IPF) and emphysema (CPFE) are independently related to poor survival. CPFE is a condition with features of both pulmonary fibrosis and emphysema. Here, we evaluated the effect of CPFE and IPF alone on the outcomes of NSCLC patients. Patients and methods We retrospectively evaluated 283 patients with CPFE or IPF who were diagnosed with NSCLC between November 2003 and February 2018 at two tertiary care hospitals in South Korea. Patients were classified into CPFE and IPF groups according to chest computed tomography findings. Results One-hundred-and-seven patients (37.8%; mean age: 70.1 years; men 97.2%) had CPFE. Compared with IPF patients, CPFE patients had a heavier smoking history; lower diffusing capacity of carbon monoxide (78.0% vs 64.8%, p < 0.001), and lower forced expiratory volume in 1 s. Of all patients with NSCLC, 71.7% overall died during the follow-up period; 71.6% died in the CPFE group and 72.0% in the IPF group. Multivariate logistic regression analysis showed that CPFE (odds ratio [OR]: 2.26, 95% confidence interval [CI]: 1.09–4.69; P = 0.029) was significantly correlated with acute exacerbations (AEs). In a Cox proportional hazards analysis, stage > III NSCLC, higher Eastern Cooperative Oncology Group performance status, and higher gender–age–physiology index score was related to higher mortality. However, CPFE was not related to a higher mortality rate in univariate (hazard ratio [HR]: 1.00; 95% CI: 0.75–1.32, P = 0.972) or multivariate analysis (HR: 0.89; 95% CI: 0.66–1.21, P = 0.466). Conclusions AE risk, but not all-cause mortality, was higher in patients with CPFE and NSCLC than in those with IPF and NSCLC. Physicians should be aware of the exaggerated risk of AE in patients with concomitant CPFE and NSCLC.

Download Full-text